Join us for an insightful precision oncology educational session, featuring key highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Dr Stephen Luen and the Early Drug Development (EDD) fellows from the EDD / Phase 1 Cancer Clinical Trials Unit will share emerging data on ctDNA-driven strategies to inform novel therapeutic approaches across a range of cancer types.
Don’t miss this opportunity to deepen your understanding and stay at the forefront of translational cancer research and clinical innovation.
The VCCC Alliance Precision Oncology Forum is an educational seminar series aimed at providing scientists and clinicians with the latest concepts, evidence-based knowledge, and their clinical application in precision oncology.
Sessions are conducted via a hybrid format and typically include an educational presentation accompanied by case reviews to illustrate key points.
Dr Huiling Xu
Senior Research Fellow, Peter MacCallum Cancer Centre
Dr Joep Vissers
Curation Scientist Team Leader, the University of Melbourne
ctDNA in patients with stage 2/3 HR+HER2- breast cancer treated with neoadjuvant endocrine therapy in the I-SPY2 endocrine optimization pilot (EOP) trial
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial
Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project
Camizestrant + CDK4/6i for treatment of emergent ESR1 mutations during first-line endocrine-based therapy ahead of disease progression in patients with HR+HER2- advanced breast cancer: SERENA-6
